Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma

European Journal of Clinical Pharmacology

Volumn 72, Issue 2, 2016, Pages 153-161

  Mu, Song ^a   Kuroda, Yoshiaki ^b   Shibayama, Hirohiko ^c   Hino, Masayuki ^d   Tajima, Takeshi ^e   Corrado, Claudia ^a   Lin, Rong ^a   Waldron, Edward ^a   Binlich, Florence ^e   Suzuki, Kenshi ^f  

^a NOVARTIS PHARMA AG   (Switzerland)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^e NOVARTIS PHARMA K K   (Japan)

^f JAPANESE RED CROSS MEDICAL CENTER   (Japan)

Author keywords

Clinical trials; Histone deacetylase inhibitor; Panobinostat; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; PANOBINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; ENZYME INDUCTION; FATIGUE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION; VOMITING; AGED; BLOOD; CLINICAL TRIAL; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROXAMIC ACIDS; INDOLES; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL;

EID: 84954203949     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1967-z     Document Type: Article

References (25)

1. Andreu-Vieyra CV, Berenson JR (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol 5(6):197-210. doi: 10.1177/2040620714552614
2. Libby EN, Becker PS, Burwick N, Green DJ, Holmberg L, Bensinger WI (2015) Panobinostat: a review of trial results and future prospects in multiple myeloma. Expert Rev Hematol 8(1):9-18. doi: 10.1586/17474086.2015.983065
3. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280(2):233-241. doi: 10.1016/j.canlet.2009.02.019
4. Anne M, Sammartino D, Barginear MF, Budman D (2013) Profile of panobinostat and its potential for treatment in solid tumors: an update. Oncol Targets Ther 6:1613-1624. doi: 10.2147/OTT.S30773
5. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC (2013) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res 37(7):829-837. doi: 10.1016/j.leukres.2013.03.006
6. Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG (2013) Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther 12(6):1140-1150. doi: 10.1158/1535-7163.mct-12-1151
7. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Blade J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15(11):1195-1206. doi: 10.1016/S1470-2045(14)70440-1
8. San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC (2013) Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol 31(29):3696-3703. doi: 10.1200/JCO.2012.46.7068
9. Sharma S, Beck J, Mita M, Paul S, Woo MM, Squier M, Gadbaw B, Prince HM (2013) A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Invest New Drugs 31(4):974-985. doi: 10.1007/s10637-013-9930-2
10. Clive S, Woo MM, Nydam T, Kelly L, Squier M, Kagan M (2012) Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol 70(4):513-522. doi: 10.1007/s00280-012-1940-9
11. Morita S, Oizumi S, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y (2012) Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 30(5):1950-1957. doi: 10.1007/s10637-011-9751-0
12. DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, Giles FJ, Scott JW, Parker K, Liu A, Woo M, Atadja P, Mishra KK, Ottmann OG (2013) Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia 27(8):1628-1636. doi: 10.1038/leu.2013.38
13. Slingerland M, Hess D, Clive S, Sharma S, Sandstrom P, Loman N, Porro MG, Mu S, Waldron E, Valera SZ, Gelderblom H (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemother Pharmacol 74(5):1089-1098. doi: 10.1007/s00280-014-2594-6
14. Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol 75(1):87-95. doi: 10.1007/s00280-014-2612-8
15. Feld R, Woo MM, Leighl N, Shepherd FA, Beck JT, Zhao L, Gazi L, Hengelage T, Porro MG, Nayak A (2013) A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol 72(4):747-755. doi: 10.1007/s00280-013-2237-3
16. Hamberg P, Woo MM, Chen LC, Verweij J, Porro MG, Zhao L, Li W, van der Biessen D, Sharma S, Hengelage T, de Jonge M (2011) Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68(3):805-813. doi: 10.1007/s00280-011-1693-x
17. Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, Porro MG, Woo MM, Lewis LD (2012) The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 69(2):555-562. doi: 10.1007/s00280-011-1758-x
18. Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H, Kobayashi K, Yamamoto N (2012) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 30(3):1096-1106. doi: 10.1007/s10637-011-9666-9
19. de Estella-Hermoso MA, Imbuluzqueta I, Campanero MA, Gonzalez D, Vilas-Zornoza A, Agirre X, Lana H, Abizanda G, Prosper F (2011) Development and validation of ultra high performance liquid chromatography-mass spectrometry method for LBH589 in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 879:3490-3496
20. McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C (2000) In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 68(4):356-366. doi: 10.1067/mcp.2000.110215
21. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268(24):6346-6358
22. San Miguel J, Hungria VT, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee J-H, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Binlich F, Richardson PG (2014) Efficacy and safety based on duration of treatment of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma in the Phase 3 Panorama 1 Study. ASH Annual Meeting, Blood,124: Abstract474.
23. Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R (2012) Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol 40(7):564-574. doi: 10.1016/j.exphem.2012.02.004
24. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431-440. doi: 10.1016/S1470-2045(11)70081-X
25. Richardson PG, Hungria VTM, Yoon S-S, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Panneerselvam A, Redhu S, Corrado C, Binlich F, San Miguel JF (2014) Characterization of the incidence and management of gastrointestinal toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Blood 124: Abstract 2120.